In the case of midostaurin-pretreated ASM/MCL, the combinations “avapritinib + CDK4/CDK6 inhibitor” or “nintedanib + CDK4/CDK6 inhibitor” may be preferable, as these inhibitors show higher affinity to D816V-mutated KIT than midostaurin. The gene discussed is CDK6; the disease is mantle cell lymphoma.